Community-acquired pneumonia (CAP), health-care-associated pneumonia (HCAP), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP)pneumonia (VAP)
Conditions
Interventions
None listed
Sponsors
Central Japan Lung Study Group
Department of Infectious Diseases, Nagoya University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The presence of a new infiltrate on a chest X-ray, or a computed tomography scan, plus at least 2 of the following criteria: 1) cough or purulent sputum, 2) pleuritic chest pain, 3) dyspnea, 4) fever or hypothermia (temperature >= 38 degrees or < 35 degrees), 5) white blood cell count >= 10,000 /mm3 or < 4,000 /mm3, and 6) hypoxemia (SpO2 < 90% or PaO2 < 60 Torr) or decline in oxygenation.
Exclusion criteria
Exclusion criteria: 1) Patients who do not receive initial empirical antibiotic treatment. 2) Patients with obstructive pneumonia. 3) Pneumonia occurred in other hospitals and patients who were transferred from their hospitals with a tendency to improve. 4) Patients whose pneumonia recurred within 3 days after the last day of antibiotic treatment of a preceding pneumonia episode. 5) Patients who receive the treatment in an outpatient clinic. 6) Patients who are less than 20 years old.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Antimicrobial susceptibilities in identified microbes. 2) The frequency of each identified microbe and those proportion of drug resistance in patients with CAP, HCAP, HAP, and VAP. 3) Mechanisms for drug resistance in identified microbes in patients with CAP, HCAP, HAP, and VAP. 4) Differences in molecular epidemiological findings in identified microbes among patients with CAP, HCAP, HAP, and VAP. | — |
Countries
Japan
Contacts
Public ContactYuichiro Shindo
Nagoya University Hospital Respiratory Medicine
Outcome results
None listed